Bayer Launches Stivarga In Malaysia And Singapore For Terminal Colorectal Cancer Patients To Prolong Survival
This article was originally published in PharmAsia News
Bayer built upon approvals in the U.S., Europe and Japan to launch Stivarga for the first time in Southeast Asia. Well-established cancer treatment centers in Singapore and Malaysia attract patients in the region as well as far afield from the Middle East.
You may also be interested in...
Bayer Sees Xarelto Being Profitable In 2014 As New Drugs Deliver
Bayer’s pharma sales surged in the second quarter, driven by heart drug Xarelto, new ophthalmic Eylea and cancer treatment Stivarga, prompting the German blue chip to raise its sales forecast for medicines this year and assert that its new oral anticoagulant probably will become profitable in 2014.
Bayer/Onyx Stick To Advanced Cancer Setting With Stivarga’s GIST Indication
New indication for third-line gastrointestinal stromal tumors, an area of high unmet need, builds on candidate’s initial approval in advanced colon cancer.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.